Spencer R. Berthelsen - Jun 17, 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Spencer R. Berthelsen
Stock symbol
IONS
Transactions as of
Jun 17, 2024
Transactions value $
-$76,160
Form type
4
Date filed
6/20/2024, 05:52 PM
Previous filing
Jul 19, 2023
Next filing
Jul 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $568K +16K +10.87% $35.53 163K Jun 17, 2024 Direct
transaction IONS Common Stock Sale -$645K -16K -9.8% $40.29 147K Jun 17, 2024 Direct
holding IONS Common Stock 70 Jun 17, 2024 by Daughter F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -16K -100% $0.00* 0 Jun 17, 2024 Common Stock 16K $35.53 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.